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Classical pharmacology has been the basis for the discovery of new chemical entities with therapeutic
effects for decades. In natural product research, compounds are generally tested in vivo only after full
in vitro characterization. However drug screening using this methodology is expensive, time-consuming
and very often inefﬁcient.
Reverse pharmacology, also called bedside-to-bench, is a research approach based on the traditional
knowledge and relates to reversing the classical laboratory to clinic pathway to a clinic to laboratory
practice. It is a trans-disciplinary approach focused on traditional knowledge, experimental observations
and clinical experiences. This paper is an overview of the reverse pharmacology approach applied to the
decoction of Argemone mexicana, used as an antimalarial traditional medicine in Mali. A. mexicana
appeared as the most effective traditional medicine for the treatment of uncomplicated falciparum
malaria in Mali, and the clinical efﬁcacy of the decoction was comparable to artesunate–amodiaquine
as previously published. Four stages of the reverse pharmacology process will be described here with a
special emphasis on the results for stage 4. Brieﬂy, allocryptopine, protopine and berberine were isolated
through bioguided fractionation, and had their identity conﬁrmed by spectroscopic analysis. The three
alkaloids showed antiparasitic activity in vitro, of which allocryptopine and protopine were selective
towards Plasmodium falciparum. Furthermore, the amount of the three active alkaloids in the decoction
was determined by quantitative NMR, and preliminary in vivo assays were conducted. On the basis of
these results, the reverse pharmacology approach is discussed and further pharmacokinetic studies
appear to be necessary in order to determine whether these alkaloids can be considered as phytochemical
markers for quality control and standardization of an improved traditional medicine made with this
plant.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Every year, there are over 200 million cases of malaria around
the globe, resulting in about 627,000 deaths. Most of them occur
in children under the age of 5 (WHO, 2011). The parasite responsi-
ble for malaria is developing resistance which will increase as a
result of drug pressure and the invasion of under-dosed fake med-
icines. The ﬁrst signs of resistance to artemisinin derivatives are
appearing on the Cambodia-Thailand border (Dondorp et al.,
2010) and will continue to spread rapidly if artemisinin-basedcombination therapies (ACT) are delivered to patients who do
not absolutely need them. Therefore, it is urgent to ﬁnd new hits
and lead compounds. But in the meantime, alternative processes
are needed to slow down as much as possible the progression of
resistance.
Most affected populations affected by malaria have little access
to western medicine and therefore turn towards the use of tradi-
tional medicinal plants for their primary health care (WHO,
2013). In Africa, there are more traditional healers than medical
doctors available for the population, especially in rural areas. Thus2 379 65
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(Abdullahi, 2011; WHO, 2013). Modern natural or synthetic anti-
malarial drugs have been mainly developed from only few plants:
various Cinchona sp. from which quinine was isolated already in
1820, and more recently the aerial parts of Artemisia annua from
which artemisinin was isolated in 1972 (Fig. 1). However, these
two plants have been used for centuries by the local population
as traditional medicine against fever in South America for Cinchona
and in Asia for Artemisia.
In the conventional drug discovery approach of natural prod-
ucts, the classical laboratory to clinic process also called bench to
bedside is used (Fig. 2). In this approach, numerous extracts,
frequently selected through ethnobotanical studies, are screened
and tested on targets which have been previously identiﬁed and
validated. However clinical observations (follow up of human sub-
jects) and experimental observations are not frequently involved.
Yet they could help discover which treatment among others, has
the best effect. The most promising extracts are analyzed, the
active compounds isolated, and their chemical structures eluci-
dated. Structure activity relationship and lead optimization by
means of chemical synthesis, molecular modeling, and ADMET
properties are carried out before the development phase, authority
approval and product launch. However, this approach is time
consuming and often very inefﬁcient. The average time and cost
of discovering, developing and launching a new drug is estimated
to 10–15 years with a cost between 800 million and 1.5 billion
US dollars. Why is it so expensive and why does it take so much
time? Thousands of natural extracts have been screened and hun-
dreds of compounds isolated during the last three decades. One
major difﬁculty seems to be that a natural active molecule has very
little chance to move to clinical studies because of poor absorption
and pharmacokinetics and/or adverse-effect proﬁle in animal
studies. As a result, time and money are spent for compounds that
ultimately cannot be further developed.
The concept of reverse pharmacology has been ﬁrst introduced
in the development of Ayurvedic medicines in India and suggested
in 1950’s for the development of a Chinese traditional medicine
(Lei and Bodeker, 2004). Moreover, such an approach has been well
reviewed in the context of natural product research by Wells
(2011). Reverse pharmacology is a transdisciplinary approach
integrating traditional knowledge, experimental observations and
clinical experiences (Fig. 3) with the aim of reversing from the clas-
sical laboratory to clinic process to a clinic to laboratory approach.
We herein present an overview of the reverse pharmacology of
Argemone mexicana L. (Papaveraceae). This plant is originated from
the USA-Mexico border but has spread to tropical and subtropical
areas around the world. It has a long history in traditional medicine
for the treatment of several ailments including tumors, warts, skin
diseases, inﬂammation, rheumatism, jaundice, leprosy, microbial
infections, and malaria (Brahmachari and Rajiv Roy, 2013). It is
used as an aqueous decoction in several African countries, includ-H
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Fig. 1. Structures of quinine and artemisinin leading to current antimalarial drugs.ing Mali where this study was undertaken. This plant appeared in a
‘‘retrospective treatment outcome’’ study as the most effective for
the treatment of uncomplicated falciparum malaria in Mali (Diallo
et al., 2006). Thus, this plant has been considered for a reverse
pharmacology approach divided into 4 stages (Fig. 4): stage 1:
Selection of the remedy, stage 2: Observational clinical trials, stage
3: Randomized control trials, and stage 4: Identiﬁcation of active
compounds (Willcox et al. 2011).
Results from stages 1–3 have been previously published
(Willcox et al., 2007; Graz et al., 2010a,b) and will be summarized
here in order to allow a better understanding of the topic. The
results of the phytochemical and preliminary in vivo results
retrieved during stage 4 are presented in detail within the Results
and discussion section of this article.
1.1. Stage 1: Selection of a remedy
Stage 1 consists of the selection of the plants used by the local
population, including the method of preparation, their administra-
tion and dosage. In the case of A. mexicana selection, this stage has
been previously detailed in the literature (Graz et al., 2010a).
Brieﬂy, a representative sample of the population (952 persons)
was interviewed in two rural districts. The recall period was kept
short, two weeks for an uncomplicated malaria episode. The anal-
ysis of patient progress under various treatments was compared:
modern and/or traditional medicine, treatment at home with tradi-
tional knowledge, in a health center or in the hospital. The plants
or substances used were recorded and analyzed. If a traditional
treatment, for example a plant preparation used alone, was
systematically followed by a rapid and complete recovery, with
no failure or important side effects, there was a good chance that
the preparation deserved further scrutiny (Graz et al., 2010a). In
that study, A. mexicana decoction appeared as the recipe associated
with the best outcome among patients with presumed uncompli-
cated malaria. No reference to toxicity from an aqueous decoction
of the aerial parts of this plant was reported by the population and
nothing was found in the literature. Before proceeding to clinical
studies, WHO guidelines state that if a product has been tradition-
ally used without demonstrated harm, no speciﬁc restrictive regu-
latory action should be undertaken unless new evidence demands
a revised risk-beneﬁt assessment (WHO, 2004). Pre-clinical toxic-
ity testing is only required for new medicinal herbal products
which contain herbs with no established traditional history of use.
1.2. Stage 2: Observational study
As the population has been using the decoction for a very long
time and the literature search did not reveal any toxicity, an obser-
vational clinical study was organized with patients who agreed to
take the traditional preparation prescribed by the local traditional
healer in Missidougou (Mali). The results of this stage have been
published by Willcox et al. (2007). In that study, the diagnosis of
uncomplicated malaria was conﬁrmed for all patients according
to pre-established criteria. Eighty patients were spread into 3
groups (A–C). Each group received a dose of decoction chosen by
the healer. Group A received a dose lower than the one tradition-
ally used. Group B and group C received the bottom and top of
the usual dose range, respectively. The lowest dose (group A) con-
sisted of 1 glass/day for 3 days, the mid-range of 1 glass 2 times
daily for 7 days, and the highest dose of 1 glass 4 times daily for
4 days and then 1 glass twice a day for 7 days. Patients were fol-
lowed up on days 1, 2, 3, 7, 14 and 28 (Willcox et al., 2007). Accord-
ing to the ‘‘Assessment and monitoring of antimalarial drug
efﬁcacy in low-transmission area for the treatment of uncompli-
cated falciparum malaria’’ established by WHO (2003), the parasite
count by day 3 should have decreased to less than 25% of that on
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7 and maintained throughout day 28. In the case of A. mexicana, the
number of parasites decreased dramatically in all groups by day 3.
However, at day 14, the majority of patients still had a measurable
parasitaemia, but at a lower level than at the start of the treatment
and lower than 2000 parasites/ll (Fig. 5). Only 7 patients had com-
plete parasite clearance at day 14 (Willcox et al., 2007). WHO also
recommends total parasite clearance but this may not be applica-
ble in high-transmission area like in Mali where the population
develops partial immunity in early life and is rapidly re-infected
even if parasite clearance is achieved. Although not required by
WHO guidelines, chemical analysis was carried out and did not
show any toxic compound in the decoction. In particular, sanguin-
arine, detected in the methanolic extract of the plant, was not
found in the decoction (Willcox et al., 2007). Furthermore, no
evidence of acute toxicity was detected at doses up to 3 g/kg of
the freeze-dried decoction in mice and rats (Guissou, 2007).Collecon of 
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Fig. 4. Diagram of the reverse pharmacology approac1.3. Stage 3: Randomized controlled trial
To test the safety and efﬁcacy of A. mexicana decoction in the
ﬁeld, a study has been conducted by Graz et al. (2010b), including
301 patients, of which 197 received the decoction and 101 the ACT
(artemisinin–amodiaquine) which is the nationally recommended
ﬁrst-line treatment against malaria in Mali. The objective of that
study was to develop a phytomedicine for home-based manage-
ment of malaria and to prevent severe malaria. It was important
to inform local communities about the effects of the tested phyto-
medicine as ﬁrst-line treatment for presumed malaria in semi-
immune individuals and not to outperform the ACT. Patients were
asked to take the treatment for one week, and if at the end of the
ﬁrst week they had largely improved but they were still experienc-
ing few symptoms such as mild fever, they were advised to take
the same treatment for a second week. For small children, sugar
was added to the decoction to improve the taste. The dose of the
ACT treatment was determined according to the patient’s weight
and given twice daily for 3 days. As a result, 89% of the patients
in the A. mexicana group and 95% of the ACT group did not need
a second-line treatment during the 28-day follow-up. No patient
died in either group during the same period. No case of severe
malaria was reported in patients aged over 5 years. In patients
under 5 years, severe malaria was detected in less than 2% in both
groups after 4 weeks. Among all severe malaria cases, none had
coma or convulsions. A similar proportion of patients experienced
side effects consisting mainly of cough and diarrhea for the A. mex-
icana group, and nausea and vomiting for the ACT group. These side
effects started earlier in the ACT group than in the A. mexicana
group and were described as mild (89%) or moderate (11%) for both
groups. No severe adverse effect was reported in either group (Graz
et al., 2010b).ized
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Fig. 5. Parasitaemia decreased in all patients treated with A. mexicana decoction
during the observational stage 2 (Willcox et al., 2007; Copyright 2013, with
permission from Oxford University Press).
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2.1. Plant material and extract preparation
Two available A. mexicana leaf batches corresponding to clinical
batches employed at stage 3 (Willcox et al., 2007) were considered
in this study. Batch AM 8, used to treat patients 190–238 was col-
lected in Missidougou, Mali in 2004, while batch AM 11, used to
treat patients 239–301 was collected in Sikasso, Mali in 2006. For
each batch, the plant was identiﬁed as A. mexicana L. (Papavera-
ceae) by Seydou Dembélé and a voucher specimen (number 873)
was deposited at the Department of Traditional Medicine in
Bamako, Mali. The extracts were prepared as described for the tra-
ditional preparation. The decoction was obtained by stirring 500 g
of batch AM 8 in 2 L of boiling distilled water for 3 h. Then, the
extract was freeze-dried to give 115 g of powder.
2.2. Vacuum liquid chromatography (VLC)
A VLC was conducted by ﬁlling a 250 mL Büchner funnel with
the stationary C18 phase LiChroprep 40–63 lm (Merck, Darms-
tadt, Germany). The support was connected to a vacuum system.
The stationary phase was ﬁrst eluted with MeOH (5  250 mL)
for conditioning followed by water (for equilibrating). The sample
was diluted in 100 mL water and introduced into the support. The
elution of the sample was ﬁrst conducted with 600 mL water, fol-
lowed by 600 mL MeOH.
2.3. Sephadex LH-20 size exclusion liquid chromatography
Size exclusion liquid chromatography was conducted using
Sephadex LH-20 gel (GE Healthcare, Uppsala, Sweden) as station-
ary phase and MeOH as the mobile phase. Fraction was diluted
in 1 mL MeOH to be applied onto the column and eluted with
100% MeOH.
2.4. Semi-preparative HPLC
Semi-preparative HPLC was used in order to purify the com-
pounds from pre-puriﬁed fractions. The equipment was a Shima-dzu LC-8A binary pump equipped with a SPD-10A VP Shimadzu
UV–Vis detector (Kyoto, Japan). The ﬂow rate was set to 10 mL/
min. For A. mexicana fractions, an Xterra Prep MS C18 OBDTM col-
umn (150  19 mm i.d., 5 lm) was employed for the separations
and the solvent system was A) Water and B) MeOH. An isocratic
mode at 5% B was applied for fraction AM 8_A_2, while an isocratic
mode at 42% was chosen for fractions AM 8_D_1 and AM 8_D_2.2.5. High resolution mass spectrometry (HRMS)
High resolution mass spectra were obtained on a Micromass-
LCT Premier Time of Flight (TOF) mass spectrometer (Waters,
MA, USA) with an electrospray interface and coupled with an
Acquity UPLC system (Waters, MA, USA). ESI conditions: capillary
voltage 2800 V, cone voltage 40 V, MCP detector voltage 2650 V,
source temperature 120 C, desolvation temperature 250 C, cone
gas ﬂow 10 L/h, desolvation gas ﬂow of 550 L/h. Detection was per-
formed in positive and negative ion modes in the m/z range 100–
1000 with a scan time of 0.25 s in centroid mode. For the dynamic
range enhancement (DRE) lockmass, a solution of leucine–enkeph-
alin (Sigma–Aldrich, Steinheim, Germany) at 5 lg/mL was infused
through the lockmass probe at a ﬂow rate of 20 lL/min with the
help of a second LC pump (Shimadzu LC-10ADvp, Duisburg, Ger-
many). The separations were carried out on Waters Acquity UPLC
columns at 30 C (BEH C18: 50 mm  1.0 mm, 1.7 lm) with the fol-
lowing solvent system: A) 0.1% formic acid–water, B) 0.1% formic
acid–acetonitrile. The gradient elution was performed at a ﬂow
rate of 300 lL/min using: 5% B for 0.3 min, 5–98% B in 4 min and
holding at 98% B for 2 min.2.6. Nuclear magnetic resonance spectrometry (NMR)
Nuclear magnetic resonance spectrometry (NMR) was used as
the main analytical method for the structural elucidation of the
isolated compounds. The 1H and 13C NMR spectra were recorded
on a Varian Inova 500 MHz spectrometer (Palo Alto, CA, USA) at
500 and 125 MHz, respectively. The instrument was controlled
by Varian VNMR software installed on a Sun workstation (Santa
Clara, CA, USA). All NMR measurements were performed in deuter-
ated solvents (Dr Glaser AG, Basel, Switzerland). The shifts are indi-
cated in ppm relative to tetramethylsilane (TMS) as an internal
standard for 1H spectra, and the deuterated solvent shift as refer-
ence for 13C spectra. In order to observe homo- and heteronuclear
correlations between proton and carbon atoms of the analytes,
complementary two dimensional (2D) experiments were per-
formed. For advanced and 2D spectra including COSY, HSQC, HMBC
and NOESY, standard pulse sequences provided in the original
VNMR software were employed.2.7. Spectroscopic data for allocryptopine
1H NMR, 500 MHz, pyridine-d5, 70 C, dH: 1.95 (3H, s, N–CH3),
2.52 (2H, brs, H-6), 2.91 (2H, brs, H-5), 3.68 (3H, s, O–CH3), 3.79
(3H, s, O–CH3), 3.80 (2H, s, H-8), 3.87 (2H, s, H-13), 6.69 (1H, s,
H-4), 5.90 (2H, s, O–CH2–O), 6.83 (1H, d, J = 8.3 Hz, H-11), 7.03
(1H, d, J = 8.3 Hz, H-12) 7.17 (1H, s, H-1).
13C NMR, 125 MHz, pyridine-d5, 70 C, dC: 32.6 (C-5), 41.9
(N–CH3), 47.3 (C-13), 51.6 (C-8), 56.3 (O–CH3), 58.6 (C-6), 61.0
(O–CH3), 102.1 (O–CH2–O), 109.3 (C-1), 111.3 (C-4), 112.1 (C-11),
126.2 (C-12), 129.3 (C-8a), 130.1 (C-12a), 133.8 (C-14a), 137.5 (C-
4a), 146.9 (C-2), 148.7 (C-9), 148.8 (C-3), 152.6 (C-10), 192.9 (C-14).
HRMS m/z 370.1635 [M+H]+ (calculated for C21H24NO5,
370.1654).
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1H NMR, 500 MHz, pyridine-d5, 70 C, dH: 1.94 (3H, s, N–CH3),
2.46 (2H, brs, H-6), 2.89 (2H, brs, H-5), 3.63 (2H, s, H-8), 3.96
(2H, s, H-13), 5.86 (2H, s, O–CH2–O), 5.90 (2H, s, O–CH2–O), 6.71
(1H, s, H-4), 6.75 (1H, d, J = 8.0 Hz, H-11), 6.77 (1H, d, J = 8.0 Hz,
H-12), 7.12 (1H, s, H-1).
13C NMR, 125 MHz, pyridine-d5, 70 C, dC: 31.7 (C-5), 41.7 (N–
CH3), 47.2 (C-13), 51.7 (C-8), 58.7 (C-6), 101.6 (O–CH2–O), 102.1
(O–CH2–O), 107.1 (C-11), 108.4 (C-1), 111.2 (C-4), 119.5 (C-8a),
126.2 (C-12), 130.4 (C-12a), 133.5 (C-4a), 137.5 (C-14a), 146.9 (C-
2), 147.3 (C-9), 147.3 (C-10), 148.7 (C-3), 194.8 (C-14).
HRMS m/z 354.1360 [M+H]+ (calculated for C20H20NO5,
354.1341).
2.9. Spectroscopic data for berberine
1H NMR, 500 MHz, DMSO-d6, 25 C, dH: 3.21 (2H, brs, H-5), 4.07
(3H, s, O–CH3), 4.10 (3H, s, O–CH3), 4.95 (2H, brs, H-6), 6.17 (2H, s,
O–CH2–O), 7.08 (1H, s, H-4), 7.80 (1H, s, H-10), 8.02 (1H, d,
J = 9.2 Hz, H-12), 8.21 (1H, d, J = 9.2 Hz, H-11), 8.96 (1H, s, H-13),
9.90 (1H, s, H-8).
13C NMR, 125 MHz, DMSO-d6, 25 C, dC: 26.8 (C-5), 56.0 (C-6),
57.8 (O–CH3), 63.2 (O–CH3), 102.7 (O–CH2–O), 106.5 (C-1), 106.5
(C-8), 109.3 (C-4), 121.0 (C-13), 121.0 (C-14a), 124.4 (C-12),
127.7 (C-11), 131.4 (C-4a), 133.8 (C-12a), 138.2 (C-14), 144.5
(C-9), 146.6 (C-8a), 148.5 (C-2), 150.6 (C-3), 151.2 (C-10).
HRESIMS m/z 336.1222 [M]+ (calculated for C20H18NO4,
336.1236).
2.10. Quantiﬁcation of alkaloids in the decoction by quantitative NMR
For assessing linearity and accuracy of the method, a calibration
curve was established in triplicate for allocryptopine. A standard
solution was ﬁrst prepared with 9.0 mg of isolated allocryptopine
and 9.0 mg of anthracene, used as internal standard, in 1800 lL
of pyridine-d5. Successive dilutions of the standard solution were
conducted to get triplicates of ﬁve concentrations for allocrypto-
pine (5.5, 2.5, 1.7, 0.85 and 0.6 mg/mL) and anthracene (5.3, 2.4,
1.6, 0.8, 0.5 mg/mL), according to the exactly weighed mass of
standards. 1H NMR spectra were obtained using 600 lL of each
diluted solution.
For the determination of alkaloid concentration in the tradi-
tional preparation, the decoction was prepared as described for
the traditional preparation for two available clinical batches AM
8 and AM 11. The plant material was exactly weighed
(10.0000 g) and added with 100.00 mL distilled water in a
500 mL Erlenmeyer ﬂask. Flasks were weighted and allowed to boil
for 3 h. After that, the ﬂasks were weighed at room temperature in
order to establish the loss of water. Batch AM 8 provided 42.31 mL
of tea, while batch AM 11 provided 60.51 mL. The resulting tea was
ﬁltered and 3 aliquots of 10.00 mL of each batch were transferred
to individual centrifuge tube. Each sample was added with 20 mL
CH2Cl2, shaken for 5 min and centrifuged at 5000 rpm. The super-
natant was transferred to another centrifuge tube and the opera-
tion was repeated 4 times. The CH2Cl2 layers of each sample
were grouped in a 100 mL round ﬂask and evaporated to dryness.
Each sample was recovered in 600 lL pyridine-d5 for NMR analysis.
The following 1H NMR parameters were used: spectra were
recorded in the Varian Inova 500 MHz spectrometer previously
described, at 42 C. Each sample was recorded with the following
parameters: 100 scans per sample 0.20 Hz/point, pulse width
(PW) = 8.0 ls, and relaxation delay (RD) = 1.0 s. FID ﬁles were Fou-
rier transformed with the 1D NMR processor of ACDlabs 8.0.
Sweep width = 6000.60 Hz, LB = 0.3 Hz. Signal to noise (S/N) ratio
was higher than 20. Peak areas were expressed as absolute inte-grals and the start and end points of the integration of each peak
were selected manually.
2.11. In vitro biological assays
The antiplasmodial assay on chloroquine-resistant strains of
Plasmodium falciparum (PfK1) and the cytotoxic effects on human
ﬁbroblasts were conducted exactly as previously described
(Simões-Pires et al., 2009). Trypanosoma cruzi (epimastigote form
of Y strain) and Leishmania amazonensis (promastigote form of
MHOM/BR88/BA-125 Leila strain) were maintained at 25 C in liver
infusion tryptose medium (Difco, Detroit, MI, USA) supplemented
with 10% FBS, 1% hemin (Sigma, St. Louis, MO, USA), 1% R9 147med-
ium (Hyclone) and 5% sterile human urine. Epimastigotes of T. cruzi
and promastigotes of L. amazonensis were plated in 96-well plates
at 1  107 and 5  106 parasites/well, respectively, with or without
plant extracts, in non-toxic concentrations to mouse spleen cells.
After incubation at 25 C for 24 h, the number of viable parasites
was evaluated by counting in Neubauer chamber using a light
microscope. Mean values of the triplicates were calculated and
growth inhibition was given as the percentage of control values.
2.12. In vivo antiparasitic assay
NMRI mice infected with Plasmodium berghei were given a sin-
gle dose of the freeze-dried decoction of A. mexicana, berberine sul-
fate or vehicle (control). The decoction was administered orally at
3 different concentrations (375, 1125, and 3375 mg/kg). Berberine
sulfate was administered orally (at 4, 12, and 40 mg/kg) and subcu-
taneously (at 3 and 10 mg/kg). Tested samples were solubilized in
water or saline. Activity was determined comparing the number of
parasitized red blood cells (%) between test groups (n = 3) and con-
trol group (n = 3). The pilot experiment was conducted under the
rules of the Swiss Tropical and Public Health Institute (Basel,
Switzerland).
3. Results and discussion
After validation of the efﬁcacy of the decoction, the identiﬁca-
tion of the active compound(s) took place in order to provide the
basis for the standardization and quality control of the improved
traditional medicine, which corresponds to stage 4 of the reverse
pharmacology process.
The freeze-dried aqueous extract obtained from leaves of A.
mexicana (26 g) was fractionated by liquid-solid extraction in
methanol providing a MeOH insoluble fraction (AM 8_A) and a
MeOH soluble fraction (AM 8_B). AM 8_A was submitted to VLC
on C18 silica gel providing two major fractions: one from the aque-
ous elution and another one from the methanol elution (Fig. 6).
This procedure resulted in a simpliﬁed fraction (AM 8 A_2)
presenting an HPLC/UV proﬁle similar to phenolic compounds.
However, subsequent isolation steps resulted in degradation of
the compounds from fraction AM 8_A_2 and their identiﬁcation
was not possible.
The MeOH soluble fraction (AM 8_B) presented a peak corre-
sponding to berberine in an HPLC/UV analysis (Willcox et al.,
2007), and it was then inferred that other alkaloids could be pres-
ent. The dried fraction was then evaporated to dryness and recov-
ered in water to be partitioned with CH2Cl2. The alkaloid enriched
CH2Cl2 fraction (AM 8_D) was the only fraction considered active
against P. falciparum in vitro, with an IC50 value of 1.71 lg/mL.
Interestingly, when the whole freeze-dried decoction was tested
in vitro, no antiplasmodial activity could be observed (Table 1).
The fractionation of the CH2Cl2 alkaloid-containing fraction AM
8_D led to the isolation of three active alkaloids by semi-prepara-
tive HPLC: protopine, allocryptopine and berberine (Fig. 7). These
Freeze-dried
decoction
26 g
AM 8_A
13.3 g
AM 8_B
12.1 g
AM 8_A_1
7.8 g
AM 8_A_2
5.1 g
AM 8_C
11.9 g AM 8_D (CH2Cl2) 
170 mg
A5
12 
mg 
AM 8_C_2
2.4 g
AM 8_C_3
1.9 g
AM 8_D_1
84 mg
AM 8_D_2
63 mg
AM 8_D_3
19 mg
allocryptopine
16 mg 
protopine
12 mg
A4
6 mg
Degradation 
of products
Liquid-solid extraction
MeOH (5 x 100 mL)
dissolved in water
Partitioned with CH2Cl2
MPLC (5 g)
MeOH-Water 
Sephadex LH-20 
column eluted with 
MeOH 
Semi-preparative HPLC
X-terra column
MeOH-Water 
Semi-preparative 
HPLC 
X-terra column
MeOH-Water 
VLC on C18
berberine
4 mg
Semi-preparative HPLC
X-terra column
MeOH-Water 
Fig. 6. General fractionation scheme for the freeze-dried A. mexicana decoction and isolation of the alkaloids allocryptopine, protopine and berberine.
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(Israilov and Yunusov, 1986; Bentley, 1998; Chang et al.,
2003a,b); however, these 3 alkaloids together are ﬁrst reported
as the in vitro active ingredients in clinical decoction.
The isolated alkaloids were then tested not only for their anti-
plasmodial activity but also on parasites responsible for other par-
asitic diseases: American trypanosomiasis (Chagas disease) and
African animal trypanosomiasis. Cytotoxicity was also determined
on human ﬁbroblasts. The alkaloids protopine, allocryptopine and
berberine presented IC50 values against P. falciparum of 0.32, 1.46
and 0.32 lg/mL, respectively. Berberine was also active against T.
cruzi and Trypanosoma brucei brucei and showed a signiﬁcant cyto-
toxicity (Table 1).
Based on these antiplasmodial in vitro results, the following
questions needed to be answered: Are these alkaloids responsible
for the clinical efﬁcacy? Can we use these alkaloids as markers
for quality control of a traditional medicine?
Despite the potent in vitro activity of berberine, previous
studies showed that this compound was not able to decrease
parasitaemia in P. berghei-infected mice (Vennerstrom and
Klayman, 1988). In contrast, berberine signiﬁcantly reduced par-
asitaemia in Plasmodium chabaudi-infected mice (McCall et al.,
1994). According to some incomplete pharmacokinetic data from
the literature, it has been suggested that berberine has very poor
oral bioavailability in vivo. As a matter of fact, it was demon-
strated that after a single oral dose of 400 mg, the amount of
berberine in plasma is a very small part of what was adminis-
tered (Gao et al., 2013). For protopine and allocryptopine very
little pharmacokinetics data were available.
Given all the above, the next step was to conduct quantiﬁca-
tion of the active alkaloids directly in 3 clinical batches of A.
mexicana decoction. A quantitative NMR analysis was chosen
allowing the quantiﬁcation of allocryptopine, berberine and pro-
topine within a single spectrum acquisition. This is possible
because the NMR response can be made the same for all compo-nents, contrary to HPLC/UV or MS methods. In fact, the strength
of the NMR signal is proportional to the number of nuclei, thus
the number of molecules, present in the analyzed sample. More-
over, in quantitative NMR analysis, a universal reference stan-
dard can be used for the analysis of most materials. As a
consequence, quantitative determination of a speciﬁc compound
does not require pure samples for calibration, which is of great
interest for the determination of natural products not always
available as standard compounds.
Preliminary analyses were conducted to ﬁnd the best 1H NMR
conditions (solvent and temperature) for allocryptopine, protopine
and berberine. Allocryptopine and protopine are alkaloids of the
protopine-type, presenting bad resolution in the region of the
methylene protons of the ten-membered ring, especially at room
temperature. For this reason, the chosen signals were those corre-
sponding to the methylene dioxide protons of each molecule. A
comparison of spectra for the three alkaloids in pyridine-d5 at
42 C is shown in Fig. 8. Under these conditions, one of the meth-
ylene dioxide signals of protopine overlaps with that of allocrypto-
pine (dH 5.95). Since protopine has a second methylene dioxide
signal at dH 5.90, this one could be considered for quantiﬁcation
and its integral value was subtracted from that at dH 5.95, for the
quantiﬁcation of allocryptopine. Spectra used for quantitative anal-
ysis had a signal/noise ratio higher than 20, and the signals for the
three alkaloids found in the CH2Cl2-extracted decoction are
depicted in Fig. 9.
The quantitative analysis showed that 1 L of decoction, which
corresponds to a daily dose in the clinical assay, contains more
than 300 mg of the three alkaloids considered as a whole (Table 2).
Moreover, we conducted a pilot in vivo experiment with the
freeze-dried A. mexicana decoction and berberine sulfate. RPMI
mice infected with P. berghei were given a single dose of samples
either orally or subcutaneously, at different concentrations (high-
est oral dose of decoction = 3375 mg/kg). Unfortunately, no reduc-
tion of parasitaemia could be observed.
Table 1
Antiparasitic activity and cytotoxicity of fractions and compounds isolated from A. mexicana decoction.
Compound IC50 (lg/mL)
Anti-P. falciparuma Anti-T. cruzib Anti-T. b. bruceic Cytotoxicityd
Decoction >64.00 39.24 0.57 >64.00
AM 8_A >64.00 0.25 >64.00 >64.00
AM 8_B >64.00 51.42 10.08 >64.00
AM 8_C >64.00 >64.00 1.32 >64.00
AM 8_D 1.71 0.25 0.25 24.98
Protopine 0.32 >32.00 10.75 >32.00
Allocryptopine 1.46 >32.00 10.49 >32.00
Berberine 0.32 0.32 1.66 3.20
a IC50 > 16 lg/mL: inactive; 2 < IC50 < 16 lg/mL: moderately active; IC50 < 2 lg/mL: highly active.
b IC50 > 30 lg/mL: inactive; 2 < IC50 < 30 lg/mL: moderately active; IC50 < 2 lg/mL: highly active.
c IC50 > 5 lg/mL: inactive; 1 < IC50 < 5 lg/mL: moderately active; IC50 < 1 lg/mL: highly active.
d Tested on human ﬁbroblasts (MRC-5 cell line); IC50 > 30 lg/mL: not toxic; 10 < IC50 < 30 lg/mL: moderately toxic; IC50 < 10 lg/mL: highly toxic.
N+
O
O
OCH3
H3CO
Berberine
N
O
O
O
O
CH3
O
Protopine
N
CH3
O
O
O
OCH3
H3CO
Allocryptopine
1
2
3
4
5
689
10
11
12 13
14
1
2
3
4
5
9
10
11
12 13
68
1
2
3
4
5
10
11
12 13
68
Fig. 7. Chemical structure of active alkaloids obtained from the bioguided fractionation of A. mexicana decoction.
Fig. 8. Comparative 1H NMR spectra of allocryptopine, berberine and protopine (500 MHz, 42 C, pyridine-d5).
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Fig. 9. 1H NMR spectrum of an analytical sample obtained using the extraction method for the quantitative analysis of A. mexicana decoction (500 MHz, 42 C, pyridine-d5).
Table 2
Calculated concentrations of allocryptopine, protopine and berberine in the decoction of clinical batches of A. mexicana obtained by the quantitative NMR.
A. mexicana clinical batch Compound Concentration in tea (mg/mL)a % in plant (w/w)a
AM 8 Allocryptopine 0.11 ± 0.01 0.47 ± 0.03
Protopine 0.12 ± 0.02 0.51 ± 0.02
Berberine 0.11 ± 0.01 0.48 ± 0.03
AM 11 Allocryptopine 0.18 ± 0.01 1.10 ± 0.07
Protopine 0.06 ± 0.00 0.39 ± 0.01
Berberine 0.07 ± 0.01 0.43 ± 0.04
a Average ± SD.
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From an extensive research of the active substances of A. mexi-
cana, we have not found an explanation for the clinical effective-
ness of the decoction. This is not an exceptional situation:
mechanisms of action of many medicinal plants remain a mystery,
and this is true for many synthetic drugs as well. In the case of A.
mexicana, from a molecular biology perspective, the reason why
its use is associated with an excellent clinical outcome has not
been elucidated so far. It is noteworthy that at stage 4, we started
to apply a conventional method of phytochemical bioguided frac-
tionation in order to ﬁnd out the compounds responsible for the
antimalarial efﬁcacy of A. mexicana decoction. This highlights the
very narrow spectrum of in vitro tests available for malaria: it is
possible to detect direct toxicity on the parasite, but any other bio-
logical mechanism involved in the overall clinical effect cannot be
studied by current in vitro methods.
On the other hand, the reverse pharmacology research process
allowed us to avoid two mistakes: a) if we had started with animal
studies, we would have discarded A. mexicana before conducting
any human study, because animal studies did not show any anti-
malarial effects of the plant. b) if we would have studied in vitro
active substances from A. mexicana without subsequent in vivo
studies, we would have claimed that the active substances were
discovered. Given the facility with which such claims might be
established, we should re-visit claims of active substances of other
plants and ask whether these substances are in sufﬁcient quantity,
and sufﬁciently absorbed, to explain the observed clinical effects.
Even if the active compounds from A. mexicana are not known
for the moment, we think that ‘‘reverse pharmacology’’ is an inter-
esting alternative for the development of a validated phytomedi-
cine because its results have public health and health policy
implications. The primary objective of this study was not to
develop new drugs but to provide information on phytoprepara-tions already in use locally by the population. It is a complement
to existing strategies to be used in parallel with conventional drug
development.
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